Base Year
Historical Year
Forecast Year
The chronic inflammatory demyelinating polyneuropathy treatment market attained a value of USD 4.13 billion in 2023. The market is expected to rise at a CAGR of 6.9% in the forecast period of 2024-2032 and is anticipated to be worth USD 7.52 billion by 2032.
Chronic inflammatory demyelinating polyneuropathy is a rare neuroinflammatory disorder. The destruction of nerve fibre myelin sheaths and inflammation of nerve roots takes place in this disorder. The reduction of myelin causes nerve signals blockage and thus, substantial loss in the nerve fibres.
The severity of the disease, duration of disease and symptoms vary from patient to patient. The common signs and symptoms of chronic inflammatory demyelinating polyneuropathy are impaired body movements, weakness of both muscles and paralysis in extreme cases. The disfigurement in the motor and sensory functions affects both sides of the body.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
There are different variants of chronic inflammatory demyelinating polyneuropathy such as multifocal variants, pure sensory variants, distal variants, and pure motor variants. The exact cause of CIDP is still not clear, but the studies suggest, it to be an autoimmune disorder.
The diagnosis of chronic inflammatory demyelinating polyneuropathy is a bit complicated, due to the very common symptoms. Electromyography is the primary test used to analyse the velocities of nerve conduction. Lumbar puncture and MRI imaging are the additional diagnostic tests of CIDP. These tests help in the detection of enlargement and indications of pain.
Several approved treatments are used for the management of chronic inflammatory demyelinating polyneuropathy.
According to the chronic inflammatory demyelinating polyneuropathy treatment market research report, the market can be categorised into the following segments:
Market Breakup by Therapeutic Method
Market Breakup by Diagnosis
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The increasing incidence and prevalence of CIDP are driving the growth of the chronic inflammatory demyelinating polyneuropathy treatment market. According to National Organisation for Rare Disorders, every 5-7 individuals per 100,000 are diagnosed with CIDP. The rising cases of CIDP are propelling the demand for the treatment market.
The growing research and development activities will lead to the discovery of novel targeted therapies. At present, according to clinicaltrials.gov, more than thirty-eight clinical trials are under current evaluation.
The CIDP organisations and international support groups are creating awareness regarding the diagnosis and treatment of CIDP. Raising awareness and support initiatives have stimulated the growth of the market.
With technological advancements, there are innovations in diagnostic tools and interventions. This will assist in more specific and accurate detection. The advancements in diagnostic techniques are also aiding the growth of the market.
North America is anticipated to hold the maximum share in the CIDP market. Increased expenditure in the healthcare sector and greater research and developmental activities are driving the growth of the chronic inflammatory demyelinating polyneuropathy treatment market.
There are multiple therapeutic strategies approved for the management of chronic inflammatory demyelinating treatment. The available treatments suppress the immune system and thus, there are high chances of infections and other related disorders.
Glucocorticosteroids are the first-line medications for treating CIDP. These drugs are used in combination with other immunosuppressive drugs to provide more efficient treatment. Prednisone is one of the most common drugs belonging to this category.
Intravenous immunoglobin has also shown promising effects in the treatment of CIDP. This therapy increases immunity and assists in the treatment. Subcutaneous immunoglobin delivery is an alternative form of IVIG therapy.
Plasma Exchange is the chronic treatment for the management of chronic inflammatory demyelinating polyneuropathy. In this therapeutic procedure, immunoglobins and other components are extracted from the immunity system. The plasma and its constituents are also removed from the affected individual and then replaced with albumin. The blood cells are transfused back into the patient.
Immunosuppressive agents are also used for treating chronic inflammatory demyelinating polyneuropathy. Some examples of such agents are mycophenolate, cyclosporine, and azathioprine. The discovery of novel immunosuppressants is anticipated to fuel the chronic inflammatory demyelinating polyneuropathy treatment market growth.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
With the increase in disease prevalence, there is a need for novel therapeutic interventions. These new treatments are anticipated to provide lucrative opportunities in the therapeutic sector.
The clinical trials for the incorporation of monoclonal antibodies in the standard treatments are under evaluation. Monoclonal antibodies are artificially made proteins resembling the immune system’s pathogenic defence mechanism.
Rituximab, a monoclonal antibody has recently been approved by the USFDA for the treatment of multiple sclerosis and rheumatoid arthritis.
The investigation for reducing circulating immunoglobins is also under process. These studies incorporate the activity of FcRN inhibitors that will assist in the management of chronic inflammatory demyelinating polyneuropathy.
Takeda, a key player is performing the final stage of clinical trials for a recombinant therapy HYQVIA. This therapy incorporates human hyaluronidase with a ten per cent infusion of human immunoglobins. The company aims to get approvals from the USFDA and EMA by the end of 2023. If approved, this can be used as maintenance therapy for alleviating the symptoms of chronic inflammatory demyelinating polyneuropathy.
Implementing advanced technologies in healthcare has already provided enormous benefits to human health. Researchers’ tremendous efforts have anticipated a rapid increase in the approvals for recombinant therapies. Several ongoing clinical trials are emerging as a driving factor for the market growth and development.
The report gives an in-depth analysis of the key players involved in the chronic inflammatory demyelinating polyneuropathy treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapeutic Method |
|
| Breakup by Diagnosis |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of USD 4.13 billion in 2023.
The market is expected to rise at a CAGR of 6.9% in the forecast period of 2024-2032 and is anticipated to reach USD 7.52 billion by 2032.
Chronic inflammatory demyelinating polyneuropathy is a rare neuroinflammatory disorder. The destruction of nerve fibre myelin sheaths and inflammation of nerve roots takes place in this disorder.
Based on the therapeutic method, the market is segmented into corticosteroids, intravenous immunoglobulins, plasma exchange, immunotherapy, stem cell transplant, and physical therapy, among others.
The regions are North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Based on the diagnosis, the market is bifurcated into electrodiagnostic testing, nerve conduction, electromyography, spinal fluid analysis and others.
The end-users are hospitals, speciality neurological clinics, and research and academic laboratories.
The increasing prevalence of chronic inflammatory demyelinating polyneuropathy, rising awareness and growing research and development activities are driving the market growth.
North America is anticipated to hold a significant share in the market during the forecast period.
The key companies involved in the market are Grifols, SA, Octapharma AG, Baxter International Inc., Pfizer, Inc., CSL Behring, GE Neuro, MedDay Pharmaceuticals, Shire, Takeda Pharmaceuticals, Teijin Pharma, Momenta Pharmaceuticals, among others.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share